Yabao Pharmaceuticals and Sciecure Pharma Announce Strategic Partnership to Co-develop, Manufacture and Commercialize Generics for U.S. and China

BEIJING & MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--Yabao Pharmaceutical Co, Inc. (Shanghai Stock Exchange 600351) and Sciecure Pharma Inc. today announced a strategic partnership to co-develop, manufacture and commercialize high technological barrier generics medicines for both the U.S. and China markets.

Yabao Pharmaceutical and Sciecure Pharma announced partnership to co-develop generics medicines.
Tweet this
Under the terms of the agreement, Yabao will exclusively own rights to commercialize certain Sciecure Pharma-developed products in China and to manufacture for both the U.S. and China markets, while Sciecure Pharma will retain rights to commercialize in U.S. and all other markets. Financial terms were not disclosed.

"Yabao is pleased to collaborate with Sciecure Pharma, a dynamic company with extensive drug development expertise and know-how on high technological barrier controlled release formulation, to synergize with Yabao's cGMP manufacturing and leading commercialization capabilities in China," commented Dr. Peng Wang, President of R&D, Yabao Pharmaceutical Co. "Yabao is actively partnering with leading overseas companies to bring in and deliver high quality medicines with unmet needs in China. This partnership also demonstrates that Yabao's competitive R&D and manufacturing have expanded into developed markets."

"We are pleased to work with a leading Chinese pharma company like Yabao," said Dr. Nuo (Nolan) Wang, CEO of Sciecure Pharma Inc. "With current stormy policy changes in the pharmaceutical sector in China, the demand for high quality pharmaceutical products is rapidly growing. Sciecure Pharma is uniquely positioned to meet such demand through strategic partnering. We trust that our collaboration with Yabao will be synergistic and successful in quickly bringing high quality pharma products to patients in China."

About Yabao Pharmaceutical Co.

Yabao Pharmaceutical Co. (Shanghai Stock Exchange 600351) is a leading China pharmaceutical company with fully integrated development, manufacturing, and commercialization capabilities. Yabao recently has been pursuing strategic development and commercialization partnerships to bring high quality innovative or generic medicines into China. In addition to strong clinical and regulatory capabilities, Yabao has extensive expertise in formulation and API production and meets current Good Manufacturing Practice (cGMP) requirements with two manufacturing sites approved by U.S. FDA and a European agency, respectively. For more information about Yabao Pharmaceutical Co., please visit www.yabao.com.cn.

About Sciecure Pharma Inc

Sciecure Pharma, Inc. is an emerging U.S. based specialty pharmaceutical company with a focus on developing high barrier, technology based, bioequivalent generic and innovative drug products for regulated markets. Sciecure Pharma collaborates through strategic partnership with other pharmaceutical companies in the United States and China in product development, manufacturing, and sales.

Yabao Contact
Ms. Weina Liu, +86-10-5808-6285
[email protected]
Sciecure Contact
Nuo (Nolan) Wang, +001-908-723-1209
[email protected]


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.